- Home
- PSTL vs ZNTL Comparison
PSTL vs ZNTL Comparison
Compare PSTL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSTL | ZNTL |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.8M | 118.3M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSTL | ZNTL |
|---|---|---|
| Price | $15.55 | $1.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $17.38 | $5.87 |
| AVG Volume (30 Days) | 152.7K | ★ 494.2K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 6.28% | N/A |
| EPS Growth | ★ 508.95 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $91,195,000.00 | $26,865,000.00 |
| Revenue This Year | $24.54 | N/A |
| Revenue Next Year | $12.00 | N/A |
| P/E Ratio | $31.94 | ★ N/A |
| Revenue Growth | ★ 26.65 | N/A |
| 52 Week Low | $12.26 | $1.01 |
| 52 Week High | $16.50 | $3.53 |
Technical Indicators
Market Signals| Indicator | PSTL | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 46.24 |
| Support Level | $15.05 | $1.34 |
| Resistance Level | $15.64 | $1.48 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.42 | 38.24 |
Price Performance
Historical ComparisonAbout PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.